Lucid Diligence Brief: Caldera Therapeutics launches with $112.5 million in IBD
Lucid Diligence Brief: Caldera Therapeutics launches with $112.5 million in……
Lucid Diligence Brief: Novartis and SciNeuro BBB “brain-shuttle” Alzheimer’s deal
Lucid Diligence Brief: Novartis and SciNeuro BBB “brain-shuttle” Alzheimer’s…
Lucid Diligence Brief: Mirador Therapeutics $250 million Series B in immuno-fibrotic disease space
Lucid Diligence Brief: Mirador Therapeutics $250 million Series B in…
Lucid Diligence Brief: Chai Discovery and Eli Lilly biologics AI collaboration
Lucid Diligence Brief: Chai Discovery and Eli Lilly biologics AI collaboration…
Lucid Diligence Brief: Aurora Therapeutics launches to scale personalized CRISPR
Lucid Diligence Brief: Aurora Therapeutics launches to scale personalized…
Lucid Diligence Brief: AirNexis Therapeutics $200 million Series A for PDE3/4 in COPD
Lucid Diligence Brief: AirNexis Therapeutics $200 million Series A for PDE3/4…
Lucid Diligence Brief: Alveus Therapeutics $159.8 million Series A
Lucid Diligence Brief: Alveus Therapeutics $159.8 million Series A Professional…
Lucid Diligence Brief: Lilly to acquire Ventyx Biosciences
Lucid Diligence Brief: Lilly to acquire Ventyx Biosciences Professional…
Lucid Diligence Brief: Amgen acquires Dark Blue Therapeutics
Lucid Diligence Brief: Amgen acquires Dark Blue Therapeutics Professional…
Lucid Diligence Brief: Halozyme × Skye Bioscience evaluating ENHANZE + nimacimab in obesity
Lucid Diligence Brief: Halozyme × Skye Bioscience evaluating ENHANZE +…
Lucid Diligence Brief: Insilico Medicine × Servier oncology collaboration
Lucid Diligence Brief: Insilico Medicine × Servier oncology collaboration…
Lucid Diligence Brief: Zelgen × AbbVie option-to-license on alveltamig
Lucid Diligence Brief: Zelgen × AbbVie option-to-license on alveltamig…